论文部分内容阅读
目的:观察小剂量西洛他唑联合复方丹参滴丸治疗冠心病伴难治性高黏血症临床疗效。方法:63例冠心病伴难治性高黏血症患者随机分为2组。A组32例服用西洛他唑50mg,bid,口服复方丹参滴丸10粒,tid;B组31例服用西洛他唑100mg,bid,2组疗程均为16周。治疗第12及第16周末分别与治疗前各项血液流变学指标进行比较。结果:治疗第12周末及第16周末较治疗前血小板聚集率、纤维蛋白原、红细胞压积及全血黏度指标均显著降低(P<0.05),并且A组对血浆黏度的降低作用优于B组。结论:小剂量西洛他唑联合复方丹参滴丸治疗冠心病难治性高黏血症安全有效,无头痛不良反应。
Objective: To observe the clinical effect of low dose cilostazol combined with compound Danshen dripping pills in treating coronary heart disease complicated with refractory hyperviscosity. Methods: Sixty-three patients with coronary heart disease and refractory hyperviscosity were randomly divided into two groups. A group of 32 patients took cilostazol 50mg, bid, oral compound Danshen dripping pills 10, tid; B group of 31 patients taking cilostazol 100mg, bid, two groups of treatment were 16 weeks. At the end of the twelfth and the sixteenth weeks of treatment, the indexes of hemorheology before treatment were compared respectively. Results: Compared with before treatment, the platelet aggregation rate, fibrinogen, hematocrit and whole blood viscosity index decreased significantly (P <0.05) at the end of the 12th week and the 16th week of treatment, and the decrease of plasma viscosity in group A was better than that of B group. Conclusion: Cilostazol combined with compound Danshen dropping pills is safe and effective in treating refractory hyperviscosity in patients with coronary heart disease without adverse reaction to headache.